Clinical Trial

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

Name: A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer — clinical trial record (NCT07644559)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Cancer

Protocol Amendment History 1 change

notable Trial sites expanded: 1 -> 8 locations 2026-06-17

Trial Details

NCT Number	NCT07644559
Lead Sponsor	Verastem, Inc.
Conditions	Pancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS
Enrollment	180 participants
Start Date	2026-06-16
Primary Completion	2027-06 (estimated)
Study Completion	2028-12 (estimated)
Updated on ClinicalTrials.gov	2026-08-12